Abstract

We systemically evaluated the sensitivity of the hypoxia targeted 2-nitroimidazole-ICG conjugate using piperazine linker in in-vivo tumor models, which showed hypoxia can be targeted with twice higher signal strength than that of untargeted ICG.

© 2012 OSA

PDF Article